Lymphoedema Diagnostics Market Size, Share, Growth, Trends, and Global Industry Analysis: By Technology (X-ray Lymphography, Lymphoscintigraphy, Computed Tomography, Ultrasound Imaging, Magnetic Resonance Imaging, Bioimpedance Analysis, Near-infrared Fluorescence Imaging, ICG Lymphography, Fluorescein Sodium Micro lymphangiography), By Disease Type (Cancer, Cardiovascular Disease, Inflammatory Diseases, Other Diseases), By End User (Hospitals, Diagnostic Centers, Research & Academic Institutes, Other End Users) and Region Forecast 2020-2031                      

Lymphoedema Diagnostics Market size was valued at US$ 49.5 million in 2024 and is expected to reach US$ 86.5 million by 2031, growing at a significant CAGR of 8.3% from 2025-2031. The market refers to the specialized medical segment focused on diagnosing lymphoedema; a chronic condition characterized by abnormal swelling due to the accumulation of lymphatic fluid. This market encompasses various diagnostic tools and imaging technologies, such as lymphoscintigraphy, bioimpedance spectroscopy, ultrasound, and MRI, which help detect lymphatic dysfunction and assess disease progression. The growing prevalence of lymphoedema, often linked to cancer treatments, surgeries, and genetic disorders, has driven the demand for advanced diagnostic methods. Additionally, increasing awareness among healthcare professionals and patients regarding early detection and management of lymphoedema is contributing to market growth.

The market is experiencing expansion due to the rising incidence of cancer-related lymphoedema, which affects a significant number of post-mastectomy and radiation therapy patients. Technological advancements, including non-invasive imaging techniques and portable diagnostic devices, are further enhancing the efficiency and accuracy of lymphoedema detection. Additionally, government initiatives, reimbursement policies, and research funding aimed at improving lymphatic disease diagnostics are supporting market development. North America and Europe are leading in market growth due to well-established healthcare infrastructure, while emerging economies in Asia-Pacific are witnessing increased adoption of lymphoedema diagnostic technologies due to improving medical facilities and growing patient awareness.

Facts & Figures:

• According WHO, as of 2024, cancer remains a significant global health concern. In 2022, approximately 20 million new cancer cases were diagnosed worldwide, with 9.7 million resulting deaths. Projections indicate that by 2050, the number of new cancer cases could rise to 35 million annually, primarily due to population growth and aging.
• In December 2023, the National Heart, Lung, and Blood Institute (NHLBI) launched the first-ever National Commission on Lymphatic Diseases (NCLD). This initiative seeks to advance research and improve diagnostic methodologies for lymphatic disorders, including lymphoedema.

Key Developments:

• In July 2024, FUJIFILM Healthcare introduced the APERTO Lucent, an open 0.4T MRI system designed to enhance diagnostic accuracy and efficiency in lymphoedema detection. This system incorporates RADAR motion compensation technology, which reduces motion artifacts and minimizes the need for rescans, thereby improving image quality.
• In November 2023, Samsung unveiled the V6 ultrasound system, offering advanced imaging capabilities across 2D, 3D, and color modes. This system aims to provide healthcare professionals with precise diagnostic tools for conditions like lymphoedema.

Lymphoedema Diagnostics Market Segementation:

Based on the technology:

• Lymphoscintigraphy
• Near-Infrared Fluorescence Imaging
• Magnetic Resonance Imaging (MRI)
• Ultrasound Imaging
• Computed Tomography (CT)
• Others

Near-Infrared Fluorescence (NIRF) Imaging is emerging as the leading technology in the market, driven by its high precision, non-invasive nature, and real-time imaging capabilities. This technique has gained significant traction as it enables early detection of lymphatic dysfunction with minimal patient discomfort. Compared to conventional imaging methods such as lymphoscintigraphy or MRI, NIRF imaging offers superior visualization of the lymphatic system in motion, allowing for dynamic assessments rather than static snapshots. Additionally, it eliminates the need for radioactive tracers, making it a safer and more accessible option for both patients and healthcare professionals. The increasing adoption of NIRF imaging is fueled by its growing clinical applications, particularly in cancer-related lymphoedema cases. With a rising global burden of breast cancer, cervical cancer, and melanoma, there is an urgent need for highly efficient diagnostic tools that facilitate early intervention and personalized treatment planning. Furthermore, advancements in fluorescent contrast agents and portable imaging devices are enhancing the efficiency and affordability of this technology. As a result, NIRF imaging is expected to dominate the market, driven by technological innovation, increased healthcare investments, and a shift toward minimally invasive diagnostic solutions.

Based on the disease:

• Cancer
• Cardiovascular Disease
• Inflammatory Diseases
• Others

Cancer is the leading disease segment in the market, primarily driven by the high prevalence of cancer-related lymphoedema and the increasing need for early detection. Cancer treatments such as surgery, radiation therapy, and chemotherapy often damage the lymphatic system, leading to fluid retention and swelling, commonly seen in breast cancer, melanoma, cervical cancer, and prostate cancer patients. As cancer incidence continues to rise globally, the demand for advanced diagnostic techniques to detect lymphatic dysfunction early and prevent severe complications has increased significantly. The growing adoption of lymphoscintigraphy, near-infrared fluorescence imaging (NIRF), and MRI in oncology settings is further accelerating the dominance of this segment. Healthcare providers are increasingly prioritizing early intervention and personalized treatment plans, making highly accurate lymphoedema diagnostics a critical part of cancer patient management. Additionally, research initiatives and government funding aimed at improving cancer-related lymphoedema diagnostics are driving technological advancements, making these solutions more accessible and efficient. With continuous innovations in imaging technology and an increasing number of cancer survivors requiring long-term lymphatic monitoring, the cancer segment is expected to maintain its leadership position in the market for the foreseeable future.

Based on the end-user:

• Hospitals
• Diagnostic Centers
• Research and Academic Institutes 

Hospitals are the leading end-user segment in the market, driven by their advanced healthcare infrastructure, access to high-end imaging technologies, and the rising number of lymphoedema cases linked to cancer treatments and surgeries. As primary healthcare providers, hospitals play a crucial role in early diagnosis, treatment, and long-term management of lymphoedema, making them the preferred choice for patients requiring specialized diagnostic procedures. The increasing prevalence of cancer-related lymphoedema, cardiovascular diseases, and inflammatory disorders has led to a growing demand for precise and non-invasive imaging techniques such as lymphoscintigraphy, near-infrared fluorescence imaging (NIRF), and MRI, all of which are predominantly available in hospital settings. Additionally, hospitals benefit from government initiatives and funding aimed at improving diagnostic capabilities, particularly in developed regions. Multidisciplinary care teams, including oncologists, radiologists, and vascular specialists, work within hospitals to provide comprehensive lymphatic assessments, further strengthening their market dominance. The growing adoption of artificial intelligence (AI)-driven imaging solutions and portable diagnostic devices is also enhancing hospitals' ability to deliver rapid and accurate diagnostics. With continuous technological advancements and the expansion of hospital-based diagnostic services, this segment is expected to maintain its leading position in the  market.